Ruth Aranda

2.1k total citations
14 papers, 276 citations indexed

About

Ruth Aranda is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ruth Aranda has authored 14 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ruth Aranda's work include Cancer-related gene regulation (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Ferroptosis and cancer prognosis (3 papers). Ruth Aranda is often cited by papers focused on Cancer-related gene regulation (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Ferroptosis and cancer prognosis (3 papers). Ruth Aranda collaborates with scholars based in United States. Ruth Aranda's co-authors include Peter Olson, Lars D. Engstrom, James G. Christensen, David M. Briere, Jill Hallin, Niranjan Sudhakar, David Woods, Andressa L. Sodré, Harrah Chiang and Jeffrey S. Weber and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Bioorganic & Medicinal Chemistry.

In The Last Decade

Ruth Aranda

14 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruth Aranda United States 6 179 168 69 48 21 14 276
Niranjan Sudhakar United States 6 175 1.0× 170 1.0× 72 1.0× 49 1.0× 23 1.1× 9 282
Julia Perkins Smith United States 5 87 0.5× 152 0.9× 73 1.1× 54 1.1× 29 1.4× 12 253
Mara N. Zeissig Australia 7 165 0.9× 120 0.7× 88 1.3× 16 0.3× 31 1.5× 8 259
Seung‐Oe Lim United States 8 152 0.8× 146 0.9× 138 2.0× 31 0.6× 46 2.2× 10 287
Magdolna Djurec Spain 3 142 0.8× 85 0.5× 85 1.2× 17 0.4× 22 1.0× 3 211
Brenda Melendez United States 7 96 0.5× 163 1.0× 140 2.0× 20 0.4× 17 0.8× 10 245
Oliver Krieter Switzerland 9 139 0.8× 113 0.7× 53 0.8× 22 0.5× 36 1.7× 25 215
Irati Garmendia Spain 8 112 0.6× 98 0.6× 42 0.6× 44 0.9× 54 2.6× 12 219
Soma Ghosh United States 8 103 0.6× 106 0.6× 21 0.3× 54 1.1× 32 1.5× 14 192
Marta Escorihuela Spain 9 91 0.5× 185 1.1× 44 0.6× 26 0.5× 28 1.3× 12 277

Countries citing papers authored by Ruth Aranda

Since Specialization
Citations

This map shows the geographic impact of Ruth Aranda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Aranda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Aranda more than expected).

Fields of papers citing papers by Ruth Aranda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Aranda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Aranda. The network helps show where Ruth Aranda may publish in the future.

Co-authorship network of co-authors of Ruth Aranda

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Aranda. A scholar is included among the top collaborators of Ruth Aranda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Aranda. Ruth Aranda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Waters, Laura, Ruth Aranda, Krystal Moya, et al.. (2024). Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers. Cancer Research. 84(6_Supplement). 3319–3319. 2 indexed citations
2.
Waters, Laura, Ruth Aranda, Krystal Moya, et al.. (2023). Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers. Cancer Research. 83(7_Supplement). 2779–2779. 1 indexed citations
3.
Aranda, Ruth, Laura Waters, Krystal Moya, et al.. (2023). Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers. Cancer Research. 83(7_Supplement). 2778–2778. 1 indexed citations
4.
Smith, Christopher R., Ruth Aranda, James G. Christensen, et al.. (2022). Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors. Bioorganic & Medicinal Chemistry. 71. 116947–116947. 8 indexed citations
5.
Briere, David M., Shuai Li, Andrew Calinisan, et al.. (2021). The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Molecular Cancer Therapeutics. 20(6). 975–985. 109 indexed citations
6.
Smith, Christopher R., Svitlana Kulyk, Lars D. Engstrom, et al.. (2021). Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors. Cancer Research. 81(13_Supplement). LB003–LB003. 10 indexed citations
7.
Smith, Christopher R., Lars D. Engstrom, Svitlana Kulyk, et al.. (2021). Abstract P165: MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models. Molecular Cancer Therapeutics. 20(12_Supplement). P165–P165. 2 indexed citations
8.
Engstrom, Lars D., Laura Waters, Sole Gatto, et al.. (2020). Abstract 5684: Drug-anchored in vitro and in vivo CRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models. Cancer Research. 80(16_Supplement). 5684–5684. 1 indexed citations
9.
Hallin, Jill, Andrew Calinisan, Lauren Hargis, et al.. (2020). Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models. Cancer Research. 80(16_Supplement). LB–98. 1 indexed citations
10.
11.
Christensen, James G., Jay B. Fell, Jill Hallin, et al.. (2019). Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers. Molecular Cancer Therapeutics. 18(12_Supplement). C069–C069. 5 indexed citations
12.
Briere, David M., Andrew Calinisan, Ruth Aranda, et al.. (2019). Abstract LB-C09: The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model. Molecular Cancer Therapeutics. 18(12_Supplement). LB–C09. 10 indexed citations
13.
Christensen, James G., Jay B. Fell, Matthew A. Marx, et al.. (2019). Abstract LB-271: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor. Cancer Research. 79(13_Supplement). LB–271. 7 indexed citations
14.
Briere, David M., Niranjan Sudhakar, David Woods, et al.. (2017). The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunology Immunotherapy. 67(3). 381–392. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Niranjan Sudhakar Breakdown of academic impact, for papers by Julia Perkins Smith Breakdown of academic impact, for papers by Mara N. Zeissig Breakdown of academic impact, for papers by Seung‐Oe Lim Breakdown of academic impact, for papers by Magdolna Djurec Breakdown of academic impact, for papers by Brenda Melendez Breakdown of academic impact, for papers by Oliver Krieter Breakdown of academic impact, for papers by Irati Garmendia Breakdown of academic impact, for papers by Soma Ghosh Breakdown of academic impact, for papers by Marta Escorihuela
Rankless by CCL
2026